Overview

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating patients who have small cell lung cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
UNICANCER
Treatments:
Carboplatin
Etoposide
Ifosfamide
Criteria
DISEASE CHARACTERISTICS: Histologically proven small cell lung cancer Good prognosis on the
Manchester scale, with no more than 2 of the following high risk factors: Karnofsky less
than 60% Hyponatremia (low sodium) Alkaline phosphatase at least 1.5 times upper limit of
normal (ULN) LDH greater than ULN No symptomatic CNS metastases requiring corticosteroids

PATIENT CHARACTERISTICS: Age: 18 to 60 Performance status: See Disease Characteristics Life
expectancy: Not specified Hematopoietic: Neutrophil count at least 2,000/mm3 Platelet count
at least 125,000/mm3 Hepatic: See Disease Characteristics Bilirubin less than 1.25 times
upper limit of normal (ULN) SGOT/SGPT less than 1.25 times ULN Renal: Creatinine less than
ULN Cardiovascular: LVEF at least 50% No myocardial infarction within 5 years No
uncontrolled cardiac disease Pulmonary: No severe chronic obstructive pulmonary disease
Other: No neurological symptoms greater than grade 2 No severe psychoses No other
concurrent medical problems No active infection HIV negative No allergy to E. coli derived
products No prior malignancy within 5 years except basal cell skin cancer, carcinoma in
situ of the cervix, or lung or respiratory cancer in remission Not pregnant or nursing

PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior antineoplastic therapy